VRTX Vertex Pharmaceuticals

Q1 2025 10-Q

Filed: May 6, 2025Period ending Mar 31, 2025

Health Care

Pharmaceutical PreparationsSEC EDGAR

Vertex Pharmaceuticals (VRTX) 10-Q quarterly report for Q1 2025, filed with SEC EDGAR on May 6, 2025 for the fiscal period ending Mar 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q1 2025 10-Q

Risk Factors

• No newly added risk factors disclosed, risk section focuses on forward-looking statements and general uncertainties
• Regulatory risk emphasized on timing and uncertainty of clinical trial data, regulatory filings, and approvals for pipeline therapies

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$2.8B

▲ +3.0% YoY

Net Income

$646M

▼ -41.2% YoY

Net Margin

23.3%

▼ -1754bp YoY

Source: XBRL data from Vertex Pharmaceuticals Q1 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Vertex Pharmaceuticals Quarterly Reports

Q3 2025 10-Q

Q2 2025 10-Q

Get deeper insights on Vertex Pharmaceuticals

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.